4.7 Article

International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases

期刊

CLINICAL INFECTIOUS DISEASES
卷 52, 期 5, 页码 E103-E120

出版社

OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciq257

关键词

-

资金

  1. The Infectious Diseases Society of America
  2. UpToDate
  3. American Urological Association
  4. Bionorica
  5. Daiichi
  6. Sankyo
  7. Janssen Cilag
  8. Johnson Johnson
  9. OM Pharma
  10. Pierre Fabre
  11. Sanofi Aventis
  12. Zambon
  13. Mer-Lion Pharmaceuticals
  14. Rosen Pharma
  15. Cubist
  16. Pfizer Pharmaceuticals

向作者/读者索取更多资源

A Panel of International Experts was convened by the Infectious Diseases Society of America (IDSA) in collaboration with the European Society for Microbiology and Infectious Diseases (ESCMID) to update the 1999 Uncomplicated Urinary Tract Infection Guidelines by the IDSA. Co-sponsoring organizations include the American Congress of Obstetricians and Gynecologists, American Urological Association, Association of Medical Microbiology and Infectious Diseases-Canada, and the Society for Academic Emergency Medicine. The focus of this work is treatment of women with acute uncomplicated cystitis and pyelonephritis, diagnoses limited in these guidelines to premenopausal, non-pregnant women with no known urological abnormalities or co-morbidities. The issues of in vitro resistance prevalence and the ecological adverse effects of antimicrobial therapy (collateral damage) were considered as important factors in making optimal treatment choices and thus are reflected in the rankings of recommendations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据